aplaviroc   Click here for help

GtoPdb Ligand ID: 805

Synonyms: AK-602 | GW 873140 | GW873140A
Compound class: Synthetic organic
Comment: Aplaviroc was being investigated in clinical trial as a potential treatment for HIV infection. Concerns over liver toxicity [3] and low efficacy [1] lead to termination of the development project.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 3
Rotatable bonds 10
Topological polar surface area 119.41
Molecular weight 577.32
XLogP 5.53
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES CCCCN1C(=O)C(NC(=O)C21CCN(CC2)Cc1ccc(cc1)Oc1ccc(cc1)C(=O)O)C(C1CCCCC1)O
Isomeric SMILES CCCCN1C(=O)[C@H](NC(=O)C21CCN(CC2)Cc1ccc(cc1)Oc1ccc(cc1)C(=O)O)[C@@H](C1CCCCC1)O
InChI InChI=1S/C33H43N3O6/c1-2-3-19-36-30(38)28(29(37)24-7-5-4-6-8-24)34-32(41)33(36)17-20-35(21-18-33)22-23-9-13-26(14-10-23)42-27-15-11-25(12-16-27)31(39)40/h9-16,24,28-29,37H,2-8,17-22H2,1H3,(H,34,41)(H,39,40)/t28-,29-/m1/s1
1. Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, Steel H, Kleim JP, Bonny T, Millard J et al.. (2008)
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Antivir Ther (Lond.), 13 (2): 297-306. [PMID:18505181]
2. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H. (2006)
Structural and molecular interactions of CCR5 inhibitors with CCR5.
J Biol Chem, 281: 12688-12698. [PMID:16476734]
3. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N. (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
Antimicrob Agents Chemother, 52 (3): 858-65. [PMID:18070967]